Clinical Trial Update: Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the safety and efficacy of ADX-914 for moderate-to-severe atopic dermatitis, sponsored by Q32 Bio Inc; the SIGNAL-AD st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• ADX-914

Snippet

Sponsor: Q32 Bio Inc. | Conditions: Atopic Dermatitis | Phase 2 | Status: ACTIVE_NOT_RECRUITING